
  
    
      
        Background_NNP
        Wnt_NNP ligands_NNS are_VBP secreted_JJ glycoproteins_NNS that_WDT function_NN in_IN
        intracellular_NN signaling_VBG pathways_NNS to_TO regulate_VB a_DT variety_NN of_IN
        developmental_NN processes_VBZ including_VBG cell_NN growth_NN ,_, cell_NN
        differentiation_NN ,_, cell_NN polarity_NN ,_, and_CC apoptosis_NNS ._.
        Mis-regulation_NNP of_IN Wnt_NNP signaling_VBG leads_VBZ to_TO the_DT development_NN of_IN
        several_JJ human_JJ cancers_NNS ,_, including_VBG colon_NN carcinomas_NNS and_CC
        melanoma_NN [_NN 1_CD ]_NN ._. Canonical_NNP Wnt_NNP signaling_VBG initiates_NNS in_IN the_DT
        binding_VBG of_IN a_DT Wnt_NNP ligand_NN to_TO its_PRP$ cell_NN surface_NN receptor_NN ,_,
        members_NNS of_IN the_DT frizzled_JJ gene_NN family_NN ,_, along_IN with_IN the_DT
        co-receptor_JJ LRP_NNP 5_CD /_NN 6_CD [_NN 2_CD 3_CD ]_NN ,_, leading_VBG to_TO changes_NNS in_IN the_DT
        activities_NNS of_IN cytoplasmic_JJ effectors_NNS resulting_VBG in_IN the_DT
        stabilization_NN of_IN beta-catenin_JJ protein_NN ._. Beta-catenin_NNP then_RB
        accumulates_NNS in_IN the_DT nucleus_NN where_WRB it_PRP interacts_NNS with_IN its_PRP$
        transcriptional_NN co-activators_JJ ,_, members_NNS of_IN the_DT Lymphoid_NNP
        Enhancer_NNP Factor_NN /_NN T_NN Cell_NNP Factor_NN (_( LEF_NNP /_NN TCF_NNP )_) family_NN of_IN high_JJ
        mobility_NN group_NN DNA_NNP binding_JJ proteins_NNS to_TO regulate_VB gene_NN
        expression_NN [_NN 1_CD ]_NN ._. Many_JJ downstream_JJ gene_NN targets_NNS of_IN the_DT
        canonical_JJ Wnt_NNP /_NN beta-catenin_JJ pathway_NN have_VBP been_VBN identified_VBN
        http_NN :_: /_NN /_NN www_NN ._. stke_NN ._. org_NN ._.
        There_EX is_VBZ a_DT large_JJ family_NN of_IN Wnt_NNP ligands_NNS and_CC not_RB all_DT Wnts_NNP
        are_VBP thought_VBN to_TO function_VB in_IN the_DT same_JJ pathway_NN ._. Wnts_NNP can_MD be_VB
        operationally_RB separated_JJ into_IN two_CD classes_NNS ;_: the_DT first_JJ being_NN a_DT
        class_NN that_WDT transforms_VBZ C_NNP 57_CD mg_NN mouse_NN mammary_JJ epithelial_NN cells_NNS
        and_CC also_RB promotes_VBZ duplication_NN of_IN the_DT dorso-ventral_JJ axis_NNS
        when_WRB over-expressed_JJ in_IN Xenopus_NNP embryos_NNS ._. Wnts_NNP in_IN this_DT
        functional_JJ class_NN activate_VBP the_DT canonical_JJ Wnt_NNP /_NN beta-catenin_JJ
        pathway_NN (_( Wnt-_NNP 1_CD ,_, -_: 3_CD A_DT ,_, and_CC -_: 8_CD )_) ._. The_DT second_JJ functional_JJ group_NN
        of_IN Wnts_NNP does_VBZ not_RB transform_VB C_NNP 57_CD mg_NN cells_NNS nor_CC promote_VB axis_NNS
        duplication_NN ._. Instead_RB ,_, when_WRB over-expressed_JJ in_IN frog_NN or_CC fish_NN
        embryos_NNS ,_, these_DT Wnts_NNP perturb_NN the_DT movements_NNS of_IN gastrulation_NN ._.
        Wnts_NNP in_IN this_DT class_NN have_VBP been_VBN shown_VBN to_TO signal_VB in_IN a_DT
        non-canonical_JJ Wnt_NNP signaling_VBG pathway_NN ,_, the_DT Wnt_NNP /_NN Ca_MD 2_CD +_NN pathway_NN
        (_( Wnt-_NNP 5_CD a_DT ,_, -_: 4_CD ,_, -_: 11_CD )_) ._. The_DT Wnt_NNP /_NN Ca_MD 2_CD +_NN pathway_NN has_VBZ been_VBN shown_VBN to_TO
        increase_VB intracellular_NN Ca_MD 2_CD +_NN levels_NNS in_IN zebrafish_NN embryos_NNS [_NN 4_CD
        ]_NN and_CC to_TO activate_VBP PKC_NNP and_CC CamKII_NNP in_IN Xenopus_NNP embryos_NNS [_NN 5_CD 6_CD ]_NN
        as_RB well_RB as_IN in_IN human_JJ melanomas_NNS [_NN 7_CD ]_NN ._. Moreover_RB ,_, it_PRP may_MD
        activate_VBP Cdc_NNP 42_CD [_NN 8_CD ]_NN and_CC JNK_NNP [_NN 9_CD ]_NN ._. It_PRP is_VBZ important_JJ to_TO
        emphasize_VB that_IN whether_IN Wnts_NNP activate_VBP distinct_JJ responses_NNS and_CC
        likely_JJ pathways_NNS is_VBZ context-dependent_JJ ,_, and_CC thus_RB in_IN other_JJ
        contexts_NNS a_DT given_VBN Wnt_NNP may_MD activate_VBP another_DT pathway_NN ._.
        Vertebrate_NNP Wnts_NNP signal_NN through_IN frizzled_JJ receptors_NNS that_IN
        in_IN some_DT experimental_JJ contexts_NNS (_( e_SYM ._. g_SYM ._. ,_, without_IN co-expressing_JJ
        LRP_NNP 5_CD /_NN 6_CD )_) preferentially_RB activate_VBP the_DT Wnt_NNP /_NN beta-catenin_JJ or_CC
        Wnt_NNP /_NN Ca_MD 2_CD +_NN pathways_NNS [_NN 5_CD ]_NN ._. Interestingly_RB ,_, Wnt-_NNP 5_CD a_DT may_MD couple_NN
        to_TO either_CC pathway_NN depending_VBG on_IN which_WDT frizzled_JJ receptor_NN is_VBZ
        present_JJ ._. When_WRB co-expressed_JJ with_IN human_JJ frizzled-_NN 5_CD ,_, Wnt-_NNP 5_CD a_DT
        can_MD induce_VB a_DT secondary_JJ axis_NNS in_IN Xenopus_NNP [_NN 10_CD ]_NN ._. In_IN other_JJ
        assays_NNS ,_, however_RB ,_, Wnt-_NNP 5_CD a_DT along_IN with_IN rat_NN frizzled_JJ 2_CD (_( Rfz-_NNP 2_LS )_)
        increases_NNS intracellular_NN Ca_MD 2_CD +_NN levels_NNS and_CC activates_NNS PKC_NNP and_CC
        CamKII_NNP [_NN 4_CD 5_CD 6_CD ]_NN ._. The_DT activation_NN of_IN Wnt_NNP /_NN Ca_MD 2_CD +_NN signaling_VBG by_IN
        Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD seems_VBZ to_TO be_VB antagonistic_JJ to_TO the_DT canonical_JJ
        Wnt_NNP signaling_VBG pathway_NN ._. Specifically_RB ,_, Wnt-_NNP 5_CD a_DT expression_NN
        inhibits_NNS ectopic_JJ Wnt-_NNP 8_CD induction_NN of_IN secondary_JJ axis_NNS
        formation_NN in_IN Xenopus_NNP embryos_NNS [_NN 11_CD ]_NN ._. Supportingly_NNP ,_, the_DT
        endogenous_JJ expression_NN of_IN Wnt-_NNP 5_CD a_DT maintains_VBZ C_NNP 57_CD mg_NN cells_NNS in_IN a_DT
        normal_JJ growth_NN state_NN since_IN anti-sense_JJ Wnt-_NNP 5_CD a_DT mimics_VBZ Wnt-_NNP 1_CD
        transformation_NN of_IN C_NNP 57_CD mg_NN cells_NNS [_NN 12_CD ]_NN ._. This_DT data_NNS suggests_VBZ
        that_IN Wnt-_NNP 1_CD and_CC Wnt-_NNP 5_CD a_DT work_NN in_IN an_DT opposing_VBG manner_NN in_IN some_DT
        cellular_JJ contexts_NNS ._. This_DT potential_JJ role_NN of_IN Wnt-_NNP 5_CD a_DT as_IN a_DT tumor_NN
        suppressor_NN is_VBZ further_RBR supported_VBN by_IN the_DT evidence_NN that_IN
        ectopic_JJ Wnt-_NNP 5_CD a_DT in_IN human_JJ uroepithelial_NN cells_NNS prevents_VBZ
        tumorigenesis_NNS when_WRB injected_VBN into_IN athymic_JJ nude_JJ mice_NNS [_NN 13_CD ]_NN
        ._.
        Much_JJ is_VBZ still_RB unknown_JJ about_IN how_WRB Wnt-_NNP 5_CD a_DT signals_NNS and_CC ,_,
        importantly_RB ,_, whether_IN it_PRP regulates_VBZ any_DT genes_NNS ._. The_DT ability_NN of_IN
        dnWnt-_NN 11_CD to_TO block_VB expression_NN of_IN some_DT genes_NNS in_IN Xenopus_NNP [_NN 6_CD ]_NN
        and_CC the_DT ability_NN of_IN Wnt-_NNP 5_CD a_DT to_TO activate_VBP the_DT Ca_MD 2_CD +_NN sensitive_JJ
        transcription_NN factor_NN nuclear_JJ factor_NN of_IN activated_VBN T_NN cells_NNS
        (_( NFAT_NNP )_) [_NN 14_CD ]_NN ,_, support_NN the_DT likelihood_NN that_IN Wnt-_NNP 5_CD a_DT can_MD
        regulate_VB gene_NN expression_NN through_IN a_DT beta-catenin-independent_JJ
        mechanism_NN ._. We_PRP sought_VBD to_TO identify_VB genes_NNS regulated_VBN by_IN Wnt-_NNP 5_CD a_DT
        and_NN compare_VB whether_IN these_DT were_VBD different_JJ from_IN canonical_JJ
        Wnt-_NNP 1_CD gene_NN targets_NNS using_VBG DNA_NNP microarray_NN analysis_NN ._.
      
      
        Results_NNS
        To_TO identify_VB downstream_JJ genes_NNS regulated_VBN by_IN Wnt-_NNP 5_CD a_DT we_PRP
        created_VBD C_NNP 57_CD mg_NN cells_NNS that_WDT stably_RB express_VB both_DT Wnt-_NNP 5_CD a_DT and_NN
        Rfz-_NNP 2_CD ,_, a_DT potential_JJ ligand_NN and_CC receptor_NN pair_NN that_IN in_IN some_DT
        assays_NNS function_VBP in_IN the_DT same_JJ signaling_VBG pathway_NN ._. We_PRP
        overexpressed_JJ Rfz-_NNP 2_CD in_IN addition_NN to_TO Wnt-_NNP 5_CD a_DT in_IN C_NNP 57_CD mg_NN cells_NNS in_IN
        order_NN to_TO augment_VB the_DT activation_NN of_IN noncanonical_JJ Wnt_NNP
        signaling_VBG ._. Both_DT have_VBP been_VBN shown_VBN to_TO elevate_NN intracellular_NN Ca_MD
        2_CD +_NN levels_NNS and_CC to_TO activate_VBP PKC_NNP and_CC CamKII_NNP [_NN 4_CD 5_CD 6_CD ]_NN ._. In_IN
        addition_NN Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD have_VBP been_VBN shown_VBN to_TO synergize_NN in_IN
        their_PRP$ induction_NN of_IN CamKII_NNP [_NN 6_CD ]_NN ._. Wnt-_NNP 1_CD /_NN C_NNP 57_CD mg_NN cells_NNS were_VBD
        also_RB used_VBN for_IN comparison_NN ,_, in_IN an_DT effort_NN to_TO identify_VB genes_NNS
        preferentially_RB regulated_VBN by_IN Wnt-_NNP 5_CD a_DT ._. C_NNP 57_CD mg_NN cells_NNS appeared_VBD to_TO
        respond_VB to_TO ectopic_JJ expression_NN of_IN both_DT Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD in_IN
        C_NNP 57_CD mg_NN cells_NNS since_IN the_DT cells_NNS exhibited_VBN a_DT moderate_JJ reduction_NN
        in_IN growth_NN rate_NN in_IN comparison_NN to_TO wildtype_NN (_( wt_NN )_) C_NNP 57_CD mg_NN cells_NNS
        as_RB well_RB as_IN Wnt-_NNP 1_CD /_NN C_NNP 57_CD mg_NN cells_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        Phenotypically_NNP the_DT Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD /_NN C_NNP 57_CD mg_NN cells_NNS were_VBD more_JJR
        spread_NN out_IN and_CC the_DT overall_JJ size_NN of_IN the_DT cells_NNS increased_VBN
        compared_VBN to_TO wt_NN C_NNP 57_CD mg_NN cells_NNS or_CC Wnt-_NNP 1_CD /_NN C_NNP 57_CD mg_NN cells_NNS (_( data_NNS not_RB
        shown_VBN )_) ._. In_IN contrast_NN ,_, ectopic_JJ expression_NN of_IN Wnt-_NNP 1_CD induced_VBD
        the_DT expected_VBN morphological_JJ transformation_NN of_IN C_NNP 57_CD mg_NN cells_NNS
        (_( data_NNS not_RB shown_VBN )_) ._. Previous_JJ reports_NNS of_IN ectopic_JJ expression_NN of_IN
        different_JJ Wnts_NNP in_IN C_NNP 57_CD mg_NN cells_NNS demonstrated_VBD Wnt-_NNP 1_CD to_TO be_VB
        highly_RB transforming_VBG whereas_IN Wnt-_NNP 5_CD a_DT failed_VBD to_TO induce_VB
        transformation_NN [_NN 15_CD 16_CD ]_NN ._. By_IN identifying_VBG downstream_JJ
        targets_NNS of_IN Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD ,_, we_PRP wanted_VBD to_TO determine_VB which_WDT
        genes_NNS are_VBP responsible_JJ for_IN these_DT phenotypic_JJ changes_NNS as_RB well_RB
        as_IN which_WDT genes_NNS might_MD be_VB targets_NNS of_IN noncanonical_JJ Wnt_NNP
        signaling_VBG ._.
        RNA_NNP isolated_VBD from_IN wt_NN C_NNP 57_CD mg_NN cells_NNS ,_, C_NNP 57_CD mg_NN cells_NNS stably_RB
        transformed_VBN by_IN Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD retroviruses_NNS ,_, and_CC C_NNP 57_CD mg_NN
        cells_NNS stably_RB transformed_VBN by_IN Wnt-_NNP 1_CD retrovirus_JJ were_VBD used_VBN for_IN
        DNA_NNP microarray_NN analysis_NN ._. Biotinylated_NNP cRNA_NN probes_NNS
        synthesized_JJ from_IN the_DT RNA_NNP were_VBD hybridized_JJ to_TO Affymetrix_NNP
        mouse_NN GeneChips_NNP Mu_NNP 11_CD k_NN subA_NN and_CC subB_NN arrays_NNS ._. Over_IN 11_CD ,_, 000_CD
        oligonucleotide_NN probe_NN sets_NNS were_VBD analysed_JJ including_VBG known_VBN
        genes_NNS and_CC ESTs_NNP ._. Two_CD independent_JJ sets_NNS of_IN experiments_NNS were_VBD
        performed_VBN that_WDT initiated_VBD from_IN the_DT growth_NN of_IN cells_NNS ._. Probe_NNP
        sets_NNS that_WDT underwent_VBD a_DT 2_CD -_: fold_VB or_CC greater_JJR change_NN in_IN the_DT
        Wnt-ligand_NNP expressing_VBG cells_NNS compared_VBN to_TO control_VB cells_NNS were_VBD
        selected_VBN for_IN further_JJ analysis_NN ._. Over_IN 90_CD genes_NNS that_WDT repeated_VBD
        in_IN both_DT experiments_NNS appeared_VBD to_TO change_VB in_IN the_DT
        Wnt-expressing_NNP cells_NNS ._. Of_IN those_DT ,_, 50_CD genes_NNS were_VBD chosen_VBN for_IN
        validation_NN by_IN an_DT independent_JJ method_NN (_( quantitative_JJ RT-PCR_NNP )_) ._.
        A_DT list_NN of_IN some_DT of_IN these_DT genes_NNS ,_, with_IN the_DT observed_VBN
        fold-changes_JJ determined_VBN by_IN DNA_NNP microarray_NN analysis_NN and_CC
        quantitative_JJ RT-PCR_NNP ,_, is_VBZ shown_VBN (_( Table_NNP 1_CD ;_: list_NN of_IN primers_NNS
        shown_VBN in_IN Table_NNP 2_LS )_) ._. Genes_NNP are_VBP separated_VBN by_IN functional_JJ
        categories_NNS with_IN the_DT greatest_JJS number_NN of_IN genes_NNS having_VBG roles_NNS
        in_IN cell_NN adhesion_NN ,_, transcriptional_NN regulation_NN ,_, and_CC
        signaling_VBG ._. The_DT list_NN of_IN genes_NNS shows_VBZ those_DT that_WDT are_VBP specific_JJ
        to_TO Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD ,_, differential_NN between_IN Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD and_CC
        Wnt-_NNP 1_CD ,_, specific_JJ to_TO Wnt-_NNP 1_CD ,_, and_CC common_JJ to_TO both_DT Wnt-_NNP 1_CD and_CC
        Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD ._. Previously_RB identified_VBN genes_NNS regulated_VBN by_IN Wnt_NNP
        signaling_VBG in_IN this_DT list_NN include_VBP fibronectin_NN [_NN 17_CD ]_NN ,_, IL-_NNP 6_CD [_NN
        18_CD ]_NN ,_, BMP-_NNP 4_CD [_NN 19_CD ]_NN ,_, groucho_NN related_VBD protein_NN [_NN 20_CD ]_NN ,_, and_CC
        Krox-_NNP 20_CD [_NN 21_CD 22_CD ]_NN ._. Since_IN Wnt-_NNP 5_CD a_DT may_MD couple_NN to_TO more_JJR than_IN
        one_CD frizzled_JJ receptor_NN ,_, different_JJ Wnt_NNP signaling_VBG pathways_NNS may_MD
        be_VB activated_VBN by_IN Wnt-_NNP 5_CD a_DT depending_VBG on_IN the_DT endogenous_JJ
        expression_NN of_IN various_JJ frizzled_JJ receptors_NNS [_NN 6_CD 10_CD ]_NN ._. Thus_RB ,_,
        it_PRP is_VBZ possible_JJ that_IN the_DT gene_NN expression_NN pattern_NN we_PRP
        identified_VBD may_MD be_VB due_JJ to_TO the_DT activation_NN of_IN both_DT canonical_JJ
        and_CC noncanonical_JJ Wnt_NNP signaling_VBG pathways_NNS ._. We_PRP compared_VBD the_DT
        Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD expression_NN profile_NN to_TO the_DT Wnt-_NNP 1_CD expression_NN
        profile_NN to_TO rule_VB out_RP genes_NNS common_JJ in_IN both_DT pathways_NNS and_CC to_TO
        identify_VB those_DT genes_NNS specific_JJ to_TO Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD ._.
        We_PRP next_RB wanted_VBD to_TO examine_VB whether_IN any_DT of_IN these_DT genes_NNS
        were_VBD regulated_VBN in_IN a_DT similar_JJ manner_NN if_IN we_PRP used_VBD alternative_JJ
        methods_NNS for_IN expressing_VBG Wnt-_NNP 1_CD or_CC Wnt-_NNP 5_CD a_DT ._. In_IN particular_JJ ,_, we_PRP
        wanted_VBD to_TO activate_VBP the_DT function_NN of_IN these_DT Wnts_NNP for_IN short_JJ
        durations_NNS rather_RB than_IN relying_VBG on_IN stable_JJ expression_NN ._. The_DT
        first_JJ approach_NN was_VBD to_TO co-culture_JJ C_NNP 57_CD mg_NN cells_NNS with_IN cells_NNS
        secreting_VBG Wnt_NNP ligand_NN ._. For_IN the_DT co-culture_JJ experiments_NNS ,_, C_NNP 57_CD mg_NN
        cells_NNS were_VBD grown_VBN together_RB with_IN Wnt-_NNP 1_CD or_CC Wnt-_NNP 5_CD a_DT expressing_VBG
        293_CD T_NN cells_NNS for_IN 24_CD hours_NNS ._. RNA_NNP was_VBD isolated_VBN and_CC quantitative_JJ
        RT-PCR_NNP was_VBD performed_VBN using_VBG primers_NNS to_TO the_DT list_NN of_IN genes_NNS
        from_IN Table_NNP 1_CD ._. The_DT majority_NN of_IN genes_NNS had_VBD little_JJ if_IN any_DT
        background_NN in_IN the_DT PCR_NNP reactions_NNS from_IN the_DT human_JJ 293_CD T_NN cell_NN
        RNA_NNP (_( data_NNS not_RB shown_VBN )_) ._. One_CD gene_NN ,_, mesothelin_NN ,_, exhibited_VBN a_DT
        3_CD -_: fold_VB induction_NN in_IN C_NNP 57_CD mg_NN cells_NNS treated_VBN with_IN the_DT Wnt-_NNP 1_CD but_CC
        not_RB the_DT Wnt-_NNP 5_CD a_DT secreting_VBG 293_CD T_NN cells_NNS (_( Figure_NN 1_CD ,_, panel_NN A_DT )_) ._.
        This_DT fold_VB change_NN was_VBD similar_JJ to_TO the_DT data_NNS obtained_VBN from_IN
        stable_JJ expression_NN with_IN Wnt-_NNP 1_CD in_IN C_NNP 57_CD mg_NN cells_NNS (_( see_VB Table_NNP 1_LS )_) ._.
        Mesothelin_NNP is_VBZ a_DT cell-surface_JJ antigen_NN of_IN unknown_JJ function_NN
        that_WDT is_VBZ expressed_VBN in_IN the_DT mesothelium_NN ._. It_PRP is_VBZ synthesized_JJ as_IN
        a_DT 69_CD kDa_NN precursor_NN that_WDT is_VBZ proteolytically_RB processed_VBN into_IN a_DT
        40_CD kDa_NN membrane_NN bound_VBN form_NN that_WDT is_VBZ
        glycosylphosphatidylinositol_NN (_( GPI_NNP )_) -_: linked_VBN and_CC a_DT 32_CD kDa_NN
        secreted_JJ form_NN ._. The_DT secreted_JJ form_NN has_VBZ been_VBN referred_VBN to_TO as_IN
        megakaryocyte_NN potentiating_VBG factor_NN (_( MPF_NNP )_) for_IN its_PRP$ ability_NN to_TO
        stimulate_VB the_DT megakaryocyte_NN colony_NN forming_VBG activity_NN of_IN
        murine_NN IL-_NNP 3_CD in_IN mouse_NN bone_NN marrow_NN cell_NN culture_NN [_NN 23_CD 24_CD ]_NN ._.
        Mesothelin_NNP expression_NN is_VBZ induced_VBN in_IN a_DT variety_NN of_IN cancers_NNS
        including_VBG ovarian_NN ,_, pancreatic_JJ ,_, lung_NN ,_, and_CC cervical_JJ cancer_NN [_NN
        25_CD 26_CD ]_NN ._. The_DT soluble_JJ portion_NN of_IN mesothelin_NN has_VBZ drawn_VBN
        attention_NN as_IN a_DT potential_JJ serum_NN tumor_NN marker_NN since_IN it_PRP is_VBZ
        highly_RB over-expressed_JJ in_IN patients_NNS with_IN ovarian_NN carcinomas_NNS
        and_CC pancreatic_JJ adenocarcinomas_NNS [_NN 27_CD 28_CD ]_NN ._.
        Stromelysin-_NNP 1_CD (_( SL-_NNP 1_LS )_) was_VBD induced_VBN almost_RB 2_CD -_: fold_VB in_IN C_NNP 57_CD mg_NN
        cells_NNS co-cultured_JJ with_IN Wnt-_NNP 5_CD a_DT secreting_VBG 293_CD T_NN cells_NNS but_CC not_RB
        with_IN Wnt-_NNP 1_CD secreting_VBG 293_CD T_NN cells_NNS (_( Figure_NN 1_CD ,_, panel_NN A_DT )_) ._. A_DT
        similar_JJ level_NN of_IN induction_NN was_VBD also_RB observed_VBN with_IN
        Wnt-_NNP 5_CD a_DT /_NN 293_CD T_NN cells_NNS co-cultured_JJ with_IN Rfz-_NNP 2_CD /_NN C_NNP 57_CD mg_NN cells_NNS (_( data_NNS
        not_RB shown_VBN )_) ,_, suggesting_VBG that_IN the_DT induction_NN of_IN SL-_NNP 1_CD is_VBZ due_JJ to_TO
        expression_NN of_IN Wnt-_NNP 5_CD a_DT and_NN not_RB only_RB to_TO Rfz-_NNP 2_CD ._. These_DT data_NNS are_VBP
        similar_JJ to_TO the_DT ~_NN 4_CD fold_VB induction_NN of_IN SL-_NNP 1_CD in_IN
        Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD /_NN C_NNP 57_CD mg_NN cells_NNS (_( Table_NNP 1_LS )_) ._. SL-_NNP 1_CD is_VBZ a_DT matrix_NN
        metalloproteinase_NN that_WDT can_MD alter_VB ECM-mediated_NNP signaling_VBG
        events_NNS during_IN development_NN [_NN 29_CD 30_CD 31_CD ]_NN ._. Both_DT SL-_NNP 1_CD and_CC
        Wnt-_NNP 5_CD a_DT have_VBP roles_NNS in_IN mammary_JJ gland_NN development_NN and_CC are_VBP
        elevated_VBD in_IN certain_JJ breast_NN cancers_NNS [_NN 32_CD 33_CD 34_CD 35_CD ]_NN ,_,
        although_IN Wnt-_NNP 5_CD a_DT is_VBZ reduced_VBN in_IN other_JJ types_NNS of_IN breast_NN cancer_NN
        [_NN 36_CD ]_NN ._.
        Since_IN Wnt-_NNP 5_CD a_DT may_MD activate_VBP both_DT vertebrate_NN Wnt_NNP pathways_NNS
        we_PRP turned_VBD to_TO an_DT approach_NN that_IN more_JJR specifically_RB would_MD
        transiently_RB activate_VBP the_DT Wnt_NNP /_NN Ca_MD 2_CD +_NN signaling_VBG pathway_NN ._. This_DT
        approach_NN involves_VBZ the_DT use_NN of_IN a_DT drug-inducible_JJ chimeric_JJ
        receptor_NN consisting_VBG of_IN the_DT extracellular_NN and_CC transmembrane_NN
        spanning_VBG portions_NNS derived_VBN from_IN the_DT hamster_NN β_NN 
        2_CD adrenergic_JJ receptor_NN (_( β_NN 
        2_CD AR_NNP )_) and_CC the_DT intracellular_NN domains_NNS
        derived_VBN from_IN Rfz-_NNP 2_CD ._. This_DT receptor_NN has_VBZ previously_RB been_VBN shown_VBN
        to_TO elevate_NN intracellular_NN Ca_MD 2_CD +_NN and_CC activate_VBP CamKII_NNP in_IN a_DT
        ligand-dependent_JJ manner_NN [_NN 6_CD 37_CD 38_CD ]_NN ._. C_NNP 57_CD mg_NN cells_NNS stably_RB
        transformed_VBN with_IN Rfz-_NNP 2_CD /_NN β_NN 
        2_CD AR_NNP retrovirus_JJ or_CC wt_NN C_NNP 57_CD mg_NN cells_NNS were_VBD
        treated_VBN overnight_JJ with_IN propranolol_NN ,_, a_DT β_NN 
        2_CD AR_NNP antagonist_NN ,_, to_TO maintain_VB the_DT
        chimeric_JJ receptors_NNS in_IN an_DT inactivated_JJ state_NN ._. Subsequently_RB ,_,
        the_DT β_NN 
        2_CD AR_NNP agonist_NN isoproterenol_NN was_VBD added_VBN for_IN
        8_CD hours_NNS at_IN which_WDT point_VBP RNA_NNP was_VBD isolated_VBN and_CC quantitative_JJ
        RT-PCR_NNP was_VBD performed_VBN ._. Supporting_VBG the_DT co-culture_JJ data_NN
        discussed_VBN above_IN ,_, SL-_NNP 1_CD exhibited_VBN almost_RB a_DT 3_CD -_: fold_VB induction_NN
        with_IN isoproterenol_NN treated_VBD Rfz-_NNP 2_CD /_NN β_NN 
        2_CD AR_NNP expressing_VBG C_NNP 57_CD mg_NN cells_NNS but_CC not_RB wt_NN
        C_NNP 57_CD mg_NN cells_NNS treated_VBN with_IN isoproterenol_NN (_( Figure_NN 1_CD ,_, panel_NN
        B_NNP )_) ._.
        SL-_NNP 1_CD appears_VBZ to_TO be_VB up-regulated_JJ by_IN Wnt-_NNP 5_CD a_DT and_NN not_RB Wnt-_NNP 1_CD
        (_( Table_NNP 1_CD and_CC Figure_NN 1_CD ,_, panel_NN A_DT )_) ._. Conversely_RB ,_, mesothelin_NN
        appears_VBZ to_TO be_VB up-regulated_JJ specifically_RB by_IN Wnt-_NNP 1_CD and_CC not_RB
        Wnt-_NNP 5_CD a_DT since_IN mesothelin_NN was_VBD not_RB induced_VBN by_IN co-culturing_JJ
        with_IN Wnt-_NNP 5_CD a_DT secreting_VBG cells_NNS or_CC by_IN activation_NN of_IN the_DT
        chimeric_JJ Rfz-_NNP 2_CD /_NN β_NN 
        2_CD AR_NNP receptor_NN (_( Figure_NN 1_CD ,_, panels_NNS A_DT and_CC
        B_NNP )_) ._. To_TO our_PRP$ knowledge_NN this_DT is_VBZ the_DT first_JJ report_NN to_TO show_VB that_IN
        two_CD genes_NNS are_VBP differentially_RB regulated_VBN by_IN two_CD different_JJ
        Wnts_NNP within_IN the_DT same_JJ cell_NN type_NN ._.
        In_IN order_NN to_TO examine_VB the_DT mechanism_NN by_IN which_WDT Wnt-_NNP 1_CD or_CC
        Wnt-_NNP 5_CD a_DT regulates_VBZ mesothelin_NN or_CC SL-_NNP 1_CD ,_, respectively_RB ,_, C_NNP 57_CD mg_NN
        cells_NNS were_VBD treated_VBN with_IN either_DT LiCl_NNP or_CC phorbol_NN myristic_JJ
        acetate_NN (_( PMA_NNP )_) ._. LiCl_NNP has_VBZ previously_RB been_VBN shown_VBN to_TO mimic_VB
        activation_NN of_IN Wnt-_NNP 1_CD signaling_VBG by_IN stabilizing_VBG beta-catenin_JJ
        through_IN its_PRP$ inhibition_NN of_IN glycogen_NN synthase_NN kinase-_NN 3_CD β_NN
        (_( GSK-_NNP 3_CD β_NN )_) ,_, a_DT kinase_NN that_WDT phosphorylates_NNS beta-catenin_JJ and_CC
        promotes_VBZ its_PRP$ degradation_NN via_IN the_DT ubiquitin_NN proteasome_NN
        pathway_NN [_NN 39_CD ]_NN ._. C_NNP 57_CD mg_NN cells_NNS treated_VBN with_IN LiCl_NNP exhibited_VBN
        elevated_VBD levels_NNS of_IN mesothelin_NN but_CC not_RB SL-_NNP 1_CD (_( Figure_NN 2_CD ,_, left_VBD
        panel_NN )_) ._. On_IN the_DT other_JJ hand_NN ,_, PMA_NNP treatment_NN of_IN C_NNP 57_CD mg_NN cells_NNS
        elevated_VBD SL-_NNP 1_CD transcript_NN levels_NNS 6_CD -_: fold_VB but_CC not_RB mesothelin_NN
        (_( Figure_NN 2_CD ,_, right_JJ panel_NN )_) ._. PMA_NNP ,_, a_DT phorbol_NN ester_NN ,_, activates_NNS
        PKC_NNP and_CC has_VBZ previously_RB been_VBN shown_VBN to_TO activate_VBP SL-_NNP 1_CD [_NN 40_CD ]_NN ._.
        It_PRP appears_VBZ that_DT mesothelin_NN is_VBZ activated_VBN by_IN Wnt-_NNP 1_CD ,_, which_WDT can_MD
        be_VB mimicked_JJ by_IN LiCl_NNP ,_, and_CC that_IN SL-_NNP 1_CD is_VBZ activated_VBN by_IN Wnt-_NNP 5_CD a_DT
        in_IN a_DT beta-catenin-independent_JJ manner_NN ,_, which_WDT can_MD be_VB mimicked_JJ
        by_IN activating_VBG PKC_NNP ._.
      
      
        Discussion_NNP
        We_PRP used_VBD DNA_NNP microarray_NN analysis_NN to_TO identify_VB genes_NNS
        regulated_VBN by_IN Wnt-_NNP 1_CD and_CC Wnt-_NNP 5_CD a_DT in_IN C_NNP 57_CD mg_NN cells_NNS ._. C_NNP 57_CD mg_NN cells_NNS
        were_VBD chosen_VBN since_IN they_PRP become_VBP transformed_VBN by_IN ectopic_JJ
        expression_NN of_IN Wnt-_NNP 1_CD and_CC by_IN loss_NN of_IN function_NN of_IN Wnt-_NNP 5_CD a_DT [_NN 12_CD
        15_CD 16_CD ]_NN ._. In_IN addition_NN ,_, Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD C_NNP 57_CD mg_NN cells_NNS exhibited_VBN
        phenotypic_JJ differences_NNS from_IN wt_NN C_NNP 57_CD mg_NN cells_NNS (_( see_VB results_NNS )_) ._.
        We_PRP focused_VBD on_IN two_CD genes_NNS that_WDT showed_VBD differential_NN regulation_NN
        by_IN Wnt-_NNP 1_CD and_CC Wnt-_NNP 5_CD a_DT since_IN their_PRP$ regulation_NN was_VBD reproducible_JJ
        using_VBG several_JJ methods_NNS to_TO activate_VBP the_DT Wnt_NNP signaling_VBG
        pathways_NNS ._. The_DT first_JJ ,_, mesothelin_NN ,_, was_VBD up-regulated_JJ by_IN Wnt-_NNP 1_CD
        both_DT by_IN stable_JJ expression_NN of_IN Wnt-_NNP 1_CD in_IN C_NNP 57_CD mg_NN cells_NNS and_CC by_IN
        co-culturing_JJ C_NNP 57_CD mg_NN cells_NNS with_IN Wnt-_NNP 1_CD secreting_VBG cells_NNS ._.
        Similarly_RB ,_, mesothelin_NN expression_NN was_VBD induced_VBN by_IN Li_NNP +_NN ,_, an_DT
        inhibitor_NN of_IN GSK-_NNP 3_CD β_NN ,_, that_WDT mimics_VBZ Wnt-_NNP 1_CD ._. Mesothelin_NNP is_VBZ
        markedly_RB over-expressed_JJ in_IN a_DT variety_NN of_IN cancers_NNS derived_VBN
        from_IN tissues_NNS of_IN the_DT mesothelium_NN ,_, including_VBG lung_NN ,_, cervix_NN ,_,
        and_CC pancreas_NN ._. Interestingly_RB ,_, mesothelin_NN expression_NN is_VBZ
        induced_VBN in_IN lung_NN ,_, ovarian_NN ,_, and_CC pancreatic_JJ carcinomas_NNS where_WRB
        constitutive_JJ activation_NN of_IN Wnt_NNP signaling_VBG is_VBZ caused_VBN by_IN
        stabilizing_VBG mutations_NNS in_IN beta-catenin_JJ [_NN 27_CD 28_CD 41_CD 42_CD 43_CD 44_CD ]_NN
        ._. The_DT induction_NN of_IN mesothelin_NN in_IN these_DT carcinomas_NNS may_MD be_VB
        due_JJ to_TO misregulation_NN of_IN Wnt_NNP signaling_VBG as_IN are_VBP other_JJ targets_NNS
        of_IN the_DT Wnt_NNP pathway_NN ,_, c-myc_JJ and_CC cyclin_NN D_NNP 1_CD ._. Mutations_NNP in_IN
        different_JJ effectors_NNS of_IN Wnt_NNP signaling_VBG have_VBP been_VBN identified_VBN
        in_IN a_DT variety_NN of_IN cancers_NNS ._. Interestingly_RB ,_, Wnt-_NNP 5_CD a_DT
        down-regulated_JJ mesothelin_NN expression_NN ,_, perhaps_RB through_IN
        antagonism_NN of_IN endogenous_JJ Wnt_NNP /_NN beta-catenin_JJ signaling_VBG ._.
        Second_JJ ,_, SL-_NNP 1_CD was_VBD up-regulated_JJ by_IN Wnt-_NNP 5_CD a_DT in_IN C_NNP 57_CD mg_NN cells_NNS ._.
        Three_CD lines_NNS of_IN evidence_NN demonstrate_VB that_IN SL-_NNP 1_CD induction_NN is_VBZ
        associated_VBN with_IN activation_NN of_IN Wnt-_NNP 5_CD a_DT signaling_VBG ._. First_LS ,_,
        C_NNP 57_CD mg_NN cells_NNS stably_RB expressing_VBG Wnt-_NNP 5_CD a_DT and_NN Rfz-_NNP 2_CD elevate_NN SL-_NNP 1_CD
        levels_NNS ._. Second_NNP C_NNP 57_CD mg_NN cells_NNS co-cultured_JJ with_IN Wnt-_NNP 5_CD a_DT
        secreting_VBG cells_NNS up-regulate_JJ SL-_NNP 1_CD ._. Third_NNP ,_, activation_NN of_IN
        chimeric_JJ Rfz-_NNP 2_CD receptors_NNS stably_RB expressed_VBD in_IN C_NNP 57_CD mg_NN cells_NNS
        augment_VB SL-_NNP 1_CD expression_NN ._. To_TO further_VB examine_VB how_WRB SL-_NNP 1_CD is_VBZ
        up-regulated_JJ by_IN Wnt-_NNP 5_CD a_DT ,_, we_PRP tested_VBD whether_IN SL-_NNP 1_CD induction_NN
        could_MD be_VB mediated_JJ by_IN downstream_JJ effectors_NNS of_IN Wnt_NNP /_NN Ca_MD
        2_CD +_NN signaling_VBG such_JJ as_IN PKC_NNP ._. Activation_NNP of_IN PKC_NNP by_IN PMA_NNP treatment_NN
        of_IN C_NNP 57_CD mg_NN cells_NNS did_VBD indeed_RB elevate_NN SL-_NNP 1_CD levels_NNS
        significantly_RB ._. SL-_NNP 1_CD is_VBZ an_DT important_JJ modulator_NN of_IN cell_NN
        adhesion_NN through_IN its_PRP$ function_NN as_IN a_DT matrix_NN metalloproteinase_NN
        that_IN degrades_NNS the_DT ECM_NNP ._. SL-_NNP 1_CD induction_NN in_IN p_NN 2_CD S_NNP cells_NNS ,_, an_DT
        untransformed_JJ mouse_NN mammary_JJ epithelial_NN cell_NN line_NN ,_, triggered_VBD
        the_DT disappearance_NN of_IN E-_NNP cadherin_NN and_CC beta-catenin_JJ from_IN
        cell-cell_JJ junctions_NNS and_CC reduced_VBD the_DT expression_NN of_IN
        beta-catenin_JJ [_NN 35_CD ]_NN ._. Wnt-_NNP 5_CD a_DT and_NN SL-_NNP 1_CD may_MD play_VB similar_JJ
        roles_NNS in_IN inhibiting_VBG cadherin-mediated_JJ cell-adhesion_JJ ,_, as_IN
        Wnt-_NNP 5_CD a_DT decreases_NNS Ca_MD 2_CD +_NN -_: dependent_JJ cell_NN adhesion_NN similar_JJ to_TO a_DT
        dominant_JJ negative_JJ cadherin_NN [_NN 11_CD ]_NN ._. The_DT regulation_NN of_IN SL-_NNP 1_CD
        by_IN Wnt-_NNP 5_CD a_DT may_MD be_VB important_JJ in_IN developmental_NN processes_VBZ such_JJ
        as_IN gastrulation_NN where_WRB Wnt-_NNP 5_CD a_DT affects_VBZ the_DT morphogenetic_JJ
        movement_NN of_IN tissues_NNS [_NN 45_CD ]_NN ._.
        Whether_IN mesothelin_NN and_CC SL-_NNP 1_CD are_VBP direct_JJ targets_NNS of_IN Wnt-_NNP 1_CD
        and_CC Wnt-_NNP 5_CD a_DT ,_, respectively_RB ,_, and_CC whether_IN alterations_NNS in_IN their_PRP$
        expression_NN are_VBP responsible_JJ for_IN the_DT observed_VBN phenotypic_JJ
        changes_NNS in_IN Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD /_NN C_NNP 57_CD mg_NN cells_NNS ,_, has_VBZ yet_RB to_TO be_VB
        determined_VBN ._. Whether_IN they_PRP are_VBP direct_JJ or_CC indirect_JJ does_VBZ not_RB
        alter_VB the_DT observation_NN that_IN the_DT expression_NN of_IN both_DT change_NN in_IN
        an_DT unexpected_JJ manner_NN in_IN response_NN to_TO these_DT two_CD Wnts_NNP ._. Much_JJ
        less_JJR is_VBZ understood_VBN about_IN Wnt-_NNP 5_CD a_DT signaling_VBG pathway_NN (_( s_VBZ )_) and_CC
        how_WRB Wnt-_NNP 5_CD a_DT signals_NNS are_NN transmitted_VBN to_TO the_DT nucleus_NN to_TO affect_VB
        gene_NN expression_NN compared_VBN to_TO the_DT canonical_JJ Wnt_NNP /_NN beta-catenin_JJ
        signaling_VBG pathway_NN ._. A_DT recent_JJ report_NN demonstrated_VBN that_IN Wnt-_NNP 5_CD a_DT
        and_NN Rfz-_NNP 2_CD can_MD induce_VB the_DT nuclear_JJ localization_NN of_IN the_DT
        transcription_NN factor_NN NF-AT_NNP [_NN 14_CD ]_NN ._. Their_PRP$ results_NNS show_VBP that_IN
        NF-AT_NNP is_VBZ a_DT downstream_JJ target_NN of_IN the_DT Wnt_NNP /_NN Ca_MD 2_CD +_NN pathway_NN and_CC
        antagonizes_NNS the_DT Wnt_NNP /_NN beta-catenin_JJ pathway_NN in_IN Xenopus_NNP
        embryos_NNS ._. The_DT SL-_NNP 1_CD promoter_NN has_VBZ putative_JJ NF-AT_NNP binding_JJ sites_NNS
        but_CC whether_IN these_DT are_VBP important_JJ for_IN Wnt-_NNP 5_CD a_DT regulation_NN
        requires_VBZ further_JJ testing_NN ._. Nevertheless_RB ,_, our_PRP$ data_NNS clearly_RB
        demonstrate_VBP that_IN different_JJ Wnts_NNP have_VBP distinct_JJ effects_NNS on_IN
        gene_NN expression_NN in_IN a_DT single_JJ cell_NN line_NN ._.
      
      
        Conclusions_NNP
        Using_VBG DNA_NNP microarray_NN analysis_NN we_PRP identified_VBD several_JJ
        genes_NNS that_WDT are_VBP differentially_RB regulated_VBN by_IN Wnt-_NNP 1_CD and_CC Wnt-_NNP 5_CD a_DT
        signaling_VBG within_IN the_DT same_JJ cell_NN type_NN ,_, C_NNP 57_CD mg_NN ._. We_PRP focused_VBD on_IN
        two_CD genes_NNS ,_, mesothelin_NN and_CC SL-_NNP 1_CD ,_, whose_WP$ regulation_NN by_IN Wnts_NNP
        was_VBD reproducible_JJ using_VBG a_DT variety_NN of_IN methods_NNS to_TO activate_VBP the_DT
        Wnt_NNP signaling_VBG pathways_NNS ._. Mesothelin_NNP ,_, a_DT potential_JJ tumor_NN serum_NN
        marker_NN ,_, was_VBD up-regulated_JJ by_IN Wnt-_NNP 1_CD and_CC down-regulated_JJ by_IN
        Wnt-_NNP 5_CD a_DT ._. SL-_NNP 1_CD ,_, a_DT matrix_NN metalloproteinase_NN ,_, was_VBD up-regulated_JJ
        by_IN Wnt-_NNP 5_CD a_DT only_RB ,_, showing_VBG that_IN Wnt-_NNP 5_CD a_DT can_MD indeed_RB affect_VB gene_NN
        expression_NN ._. Our_PRP$ data_NNS indicate_VBP that_IN different_JJ Wnts_NNP can_MD
        stimulate_VB distinct_JJ sets_NNS of_IN genes_NNS ._.
      
      
        Methods_NNP
        
          Cell_NNP Culture_NNP ,_, retroviral_NN infections_NNS ,_, and_CC DNA_NNP
          transfections_NNS
          C_NNP 57_CD mg_NN cells_NNS were_VBD grown_VBN in_IN DMEM_NNP supplemented_JJ with_IN 10_CD %_NN
          FBS_NNP and_CC 10_CD μg_NN /_NN ml_NN of_IN insulin_NN ._. 293_CD T_NN cells_NNS were_VBD grown_VBN in_IN
          DMEM_NNP supplemented_JJ with_IN 10_CD %_NN FBS_NNP ._. The_DT Wnt-_NNP 5_CD a_DT /_NN Rfz-_NNP 2_CD
          expressing_VBG C_NNP 57_CD mg_NN cell_NN line_NN and_CC the_DT Rfz-_NNP 2_CD /_NN β_NN 
          2_CD AR_NNP expressing_VBG C_NNP 57_CD mg_NN cell_NN line_NN were_VBD
          established_VBN by_IN retroviral_NN infections_NNS ._. The_DT coding_VBG region_NN
          for_IN Xenopus_NNP Wnt-_NNP 5_CD a_DT including_VBG the_DT myc_NN epitope_NN tag_NN in_IN
          pSP_NN 64_CD T_NN [_NN 45_CD ]_NN was_VBD digested_VBN with_IN BglII_NNP ,_, treated_VBN with_IN
          klenow_NN enzyme_NN and_CC ligated_JJ into_IN the_DT retroviral_NN vector_NN
          PMI-hCD_NNP 5_CD [_NN 46_CD ]_NN digested_VBN with_IN NotI_NNP and_CC treated_VBN with_IN
          Klenow_NNP enzyme_NN ._. The_DT Rfz-_NNP 2_CD coding_VBG sequence_NN from_IN plasmid_NN
          CS_NNP 2_CD +_NN [_NN 47_CD ]_NN was_VBD amplified_VBN by_IN PCR_NNP using_VBG the_DT following_JJ
          primers_NNS :_: 5_CD '_POS -_: AAAAGCGGCCGCGAGTGGGGGGCGGCGGCC-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: AAAAGTCGACGCGCCCAGCAGCGAGACCGC-_NNP 3_CD '_'' ._. The_DT PCR_NNP product_NN was_VBD
          cloned_VBN into_IN the_DT NotI_NNP and_CC SalI_NNP sites_NNS in_IN PMI-hCD_NNP 2_CD [_NN 46_CD ]_NN ._.
          The_DT coding_VBG sequence_NN for_IN the_DT Rfz-_NNP 2_CD /_NN β_NN 
          2_CD AR_NNP chimeric_JJ receptor_NN in_IN CS_NNP 2_CD +_NN [_NN 6_CD 37_CD
          ]_NN was_VBD digested_VBN with_IN EcoRI_NNP and_CC XhoI_NNP and_CC cloned_VBN into_IN
          PMI-hCD_NNP 2_CD at_IN the_DT EcoRI_NNP and_CC SalI_NNP sites_NNS ._. Generation_NNP of_IN the_DT
          retrovirus_JJ ,_, infection_NN of_IN the_DT C_NNP 57_CD mg_NN cell_NN line_NN ,_, and_CC
          enrichment_NN of_IN infected_JJ cells_NNS was_VBD performed_VBN as_IN described_VBN [_NN
          46_CD 48_CD ]_NN ._. Cell_NNP populations_NNS enriched_JJ to_TO >_NN 95_CD %_NN were_VBD used_VBN
          for_IN RNA_NNP isolation_NN ._. Total_NNP RNA_NNP was_VBD extracted_VBN using_VBG the_DT
          RNeasy_NNP Mini_NNP Kit_NNP (_( Qiagen_NNP )_) as_IN directed_VBN by_IN the_DT manufacturer_NN ._.
          Wnt-_NNP 1_CD expressing_VBG C_NNP 57_CD mg_NN cells_NNS were_VBD a_DT kind_NN gift_NN from_IN G_NNP ._.
          Shackleford_NNP ._. For_IN co-culture_JJ experiments_NNS ,_, 293_CD T_NN cells_NNS were_VBD
          transfected_JJ with_IN either_DT Xenopus_NNP Wnt-_NNP 5_CD a_DT [_NN 45_CD ]_NN ,_, mouse_NN
          Wnt-_NNP 1_CD [_NN 49_CD ]_NN ,_, or_CC CS_NNP 2_CD +_NN as_IN control_NN using_VBG the_DT lipofectamine_NN
          PLUS_NNP reagents_NNS (_( GIBCO_NNP BRL_NNP )_) as_IN directed_VBN by_IN the_DT
          manufacturer_NN ._. 24_CD hours_NNS after_IN transfection_NN the_DT
          Wnt-expressing_NNP 293_CD T_NN cells_NNS were_VBD transferred_VBN to_TO culture_NN
          dishes_NNS seeded_VBN with_IN C_NNP 57_CD mg_NN cells_NNS ._. Both_DT cell_NN types_NNS were_VBD
          plated_JJ at_IN a_DT 1_CD :_: 1_CD ratio_NN ._. Cells_NNP were_VBD co-cultured_JJ for_IN 24_CD
          hours_NNS and_CC RNA_NNP was_VBD isolated_VBN ._. For_IN induction_NN of_IN the_DT Rfz-_NNP 2_CD /_NN β_NN 
          2_CD AR_NNP chimeric_JJ receptor_NN ,_, chimeric_JJ
          receptor_NN expressing_VBG C_NNP 57_CD mg_NN cells_NNS or_CC wt_NN C_NNP 57_CD mg_NN cells_NNS were_VBD
          treated_VBN with_IN 10_CD μM_NN propranolol_NN overnight_JJ and_CC then_RB with_IN 10_CD
          μM_NN isoproterenol_NN for_IN 8_CD hours_NNS ._. Control_NN cells_NNS were_VBD treated_VBN
          with_IN 10_CD μM_NN propranolol_NN only_RB ._. For_IN Li_NNP +_NN and_CC PMA_NNP stimulation_NN
          experiments_NNS ,_, C_NNP 57_CD mg_NN cells_NNS were_VBD incubated_JJ with_IN 10_CD mM_NN LiCl_NNP ,_,
          10_CD mM_NN KCl_NNP as_IN a_DT control_NN ,_, or_CC 1_CD μM_NN PMA_NNP for_IN 6_CD hours_NNS ._. All_DT
          treatments_NNS were_VBD followed_VBN by_IN RNA_NNP extraction_NN ._.
        
        
          Oligonucleotide_NNP Array_NNP
          Total_NNP RNA_NNP was_VBD extracted_VBN using_VBG the_DT RNeasy_NNP kit_NN (_( Qiagen_NNP )_)
          according_VBG to_TO the_DT manufacturer_NN 's_POS protocols_NNS ._. Transcript_NNP
          profiling_VBG with_IN Affymetrix_NNP GeneChips_NNP (_( Affymetrix_NNP ,_, Santa_NNP
          Clara_NNP ,_, CA_NNP )_) was_VBD performed_VBN using_VBG the_DT Mu_NNP 11_CD KsubA_NNP and_CC subB_NN
          chips_NNS containing_VBG ~_NN 11_CD ,_, 000_CD probe_NN sets_NNS ._. Briefly_NNP ,_, 15_CD μg_NN of_IN
          total_JJ RNA_NNP were_VBD reverse-transcribed_JJ with_IN an_DT oligo_NN (_( dT_NN )_)
          primer_NN coupled_VBN to_TO a_DT T_NN 7_CD RNA_NNP polymerase_NN binding_JJ site_NN ._.
          Biotinylated_NNP complementary_JJ RNA_NNP (_( cRNA_NN )_) was_VBD then_RB
          synthesized_JJ from_IN the_DT resulting_VBG complementary_JJ DNA_NNP (_( cDNA_NN )_)
          with_IN the_DT use_NN of_IN T_NN 7_CD polymerase_NN ._. 30_CD μg_NN of_IN biotinylated_JJ cRNA_NN
          were_VBD then_RB randomly_RB sheared_VBN (_( to_TO an_DT approximate_JJ length_NN of_IN
          50_CD nucleotides_NNS )_) ._. Hybridization_NNP to_TO the_DT arrays_NNS and_CC
          first-pass_JJ analysis_NN of_IN the_DT scanned_JJ data_NN were_VBD performed_VBN at_IN
          the_DT PAN_NNP Facility_NNP (_( Stanford_NNP University_NNP ,_, Palo_NNP Alto_NNP ,_,
          California_NNP )_) ._.
        
        
          Reverse_VBP Transcriptase-_NNP PCR_NNP (_( RT-PCR_NNP )_) Analysis_NN
          Confirmation_NNP of_IN gene_NN expression_NN was_VBD performed_VBN using_VBG
          quantitative_JJ RT-PCR_NNP ._. cDNA_NN was_VBD created_VBN from_IN total_JJ RNA_NNP
          using_VBG the_DT ThermoScript_NNP RT-PCR_NNP System_NNP (_( Invitrogen_NNP )_) with_IN an_DT
          oligo_NN (_( dT_NN )_) 
          20_CD primer_NN ._. Minus_NNP RT_NNP controls_NNS were_VBD also_RB
          prepared_VBN similarly_RB ._. 2_LS μg_NN RNA_NNP were_VBD included_VBN in_IN each_DT
          reaction_NN in_IN a_DT total_JJ volume_NN of_IN 20_CD μl_NN ._. The_DT reaction_NN was_VBD
          performed_VBN at_IN 55_CD °_NN C_NNP for_IN 1_CD hour_NN and_CC terminated_VBN by_IN incubating_VBG
          at_IN 85_CD °_NN C_NNP for_IN 5_CD minutes_NNS ._. The_DT reaction_NN was_VBD diluted_VBN 7_CD ._. 5_CD -_: fold_VB
          in_IN water_NN and_CC 2_CD ._. 5_CD μl_NN were_VBD added_VBN to_TO the_DT PCR_NNP reaction_NN to_TO
          yield_VB a_DT total_JJ volume_NN of_IN 25_CD μl_NN ._. Since_IN nonspecific_JJ
          amplification_NN was_VBD obtained_VBN in_IN testing_VBG some_DT of_IN the_DT primers_NNS
          sets_NNS with_IN the_DT -_: RT_NNP controls_NNS ,_, optimization_NN of_IN the_DT primer_NN
          concentration_NN was_VBD performed_VBN as_IN per_IN the_DT SYBR_NNP green_JJ PCR_NNP
          protocol_NN (_( Applied_NNP Biosystems_NNP )_) ._. Three_CD concentrations_NNS of_IN
          each_DT of_IN the_DT forward_RB and_CC reverse_VB primers_NNS were_VBD used_VBN ,_, 50_CD nM_NN ,_,
          300_CD nM_NN ,_, and_CC 900_CD nM_NN ,_, to_TO obtain_VB nine_CD different_JJ
          combinations_NNS ._. The_DT amplification_NN reaction_NN was_VBD performed_VBN
          using_VBG the_DT following_NN thermocycler_NN conditions_NNS :_: 94_CD °_NN C_NNP for_IN 5_CD
          min_NN followed_VBN by_IN 40_CD cycles_NNS of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, 60_CD °_NN C_NNP for_IN 30_CD
          s_VBZ ,_, and_CC 72_CD °_NN C_NNP 30_CD s_VBZ ._. +_NN RT_NNP ,_, -_: RT_NNP ,_, and_CC no_DT template_NN controls_NNS were_VBD
          tested_VBN for_IN the_DT primer_NN concentration_NN optimization_NN and_CC
          samples_NNS were_VBD taken_VBN out_RB at_IN 20_CD ,_, 25_CD ,_, 30_CD and_CC 35_CD cycles_NNS to_TO run_VB
          on_IN 2_CD %_NN agarose_NN gels_NNS ._. The_DT combination_NN of_IN forward_RB and_CC
          reverse_VB primer_NN concentrations_NNS was_VBD selected_VBN based_VBN on_IN the_DT
          presence_NN of_IN a_DT single_JJ band_NN only_RB in_IN the_DT +_NN RT_NNP sample_NN ._. Using_VBG
          the_DT optimized_JJ primer_NN concentrations_NNS ,_, the_DT PCR_NNP reaction_NN was_VBD
          performed_VBN with_IN the_DT SYBR_NNP Green_NNP PCR_NNP Master_NNP Mix_NNP (_( Applied_NNP
          Biosystems_NNP )_) and_CC the_DT ABI_NNP Prism_NNP 7700_CD Sequence_NNP Detector_NNP
          (_( Applied_NNP Biosystems_NNP )_) ._. The_DT amplification_NN reaction_NN
          consisted_VBD of_IN the_DT following_VBG :_: 50_CD °_NN C_NNP for_IN 2_CD min_NN ,_, denaturation_NN
          at_IN 95_CD °_NN C_NNP for_IN 10_CD minutes_NNS ,_, and_CC 40_CD thermal_JJ cycles_NNS of_IN 95_CD °_NN C_NNP for_IN
          15_CD s_VBZ and_CC 60_CD °_NN C_NNP for_IN 1_CD min_NN ._. PCR_NNP quantification_NN was_VBD performed_VBN
          in_IN triplicate_NN ._. Fold_NNP induction_NN was_VBD obtained_VBN by_IN using_VBG the_DT
          ΔΔC_NN 
          t_NN method_NN in_IN which_WDT all_DT samples_NNS are_VBP
          first_JJ normalized_JJ to_TO the_DT level_NN of_IN mouse_NN hypoxanthine_NN
          phosphoribosyltransferase_NN (_( HPRT_NNP )_) in_IN each_DT sample_NN ._. Relative_NNP
          normalized_JJ units_NNS were_VBD then_RB compared_VBN between_IN the_DT
          experimental_JJ sample_NN and_CC its_PRP$ control_NN ._. The_DT primer_NN sequences_NNS
          are_VBP shown_VBN in_IN Table_NNP 2_CD ._. To_TO determine_VB the_DT specificity_NN of_IN the_DT
          primer_NN sets_NNS to_TO the_DT murine_NN mesothelin_NN and_CC SL-_NNP 1_CD targets_NNS
          genes_NNS ,_, we_PRP performed_VBD PCR_NNP using_VBG the_DT primers_NNS sets_NNS with_IN cDNA_NN
          from_IN human_JJ 293_CD T_NN cells_NNS ,_, and_CC found_VBD no_DT amplification_NN ._.
        
      
      
        Author_NN 's_POS contributions_NNS
        MP_NNP performed_VBD the_DT experiments_NNS ._. RTM_NNP supervised_VBD the_DT work_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
